BOLD-100 is under clinical development by Bold Therapeutics and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BOLD-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BOLD-100 (IT-139, NKP-1339) is under development for the treatment of solid tumors including pancreatic cancer, gastroesophageal (GE) junction carcinomas, gastric cancer, lung cancer, colon cancer, gastrointestinal tumor, treatment-resistant metastatic colorectal cancer (mCRC), bile duct cancer, pancreatic cancer, pancreatic ductal adenocarcinoma,triple-negative breast cancer, sarcomas, bladder cancer, multiple myeloma, esophageal squamous cell carcinoma (ESCC) and coronavirus disease (COVID-19). It is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]. The drug candidate is administered through intravenous route. It targets GRP78. It was also under development for the treatment of neuroendocrine tumors, non-small cell lung cancer, breast cancer, esophageal cancer, osteosarcoma, metastatic melanoma and liver cancer. It acts as PD-1 inhibitor.
Bold Therapeutics overview
Bold Therapeutics is a clinical-stage biotechnology company developing cancer therapy for the treatment of gastric, pancreatic, colorectal, and other cancers in combination with existing anti-cancer therapies. The company is headquartered in Vancouver, British Columbia.
For a complete picture of BOLD-100’s drug-specific PTSR and LoA scores, buy the report here.